2상모집 중단 (진행 중)

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

연구 개요

Patients included in the study will receive induction treatment during 6 months, followed by receive high-dose therapy followed by peripheral blood stem cell transplantation. Approximately 3 months after peripheral blood stem cell transplantation patients will receive consolidation treatment during 2 months. Subsequently patients will start maintenance treatment during 24 months. Therefore, the total duration of the treatment will be approximately 36 months.

스폰서
협력: 암젠
적응증
Smoldering Multiple Myeloma
중재
carfilzomib, Lenalidomide, Dexamethasone, Melphalan
목표 등록
90
시작일
2015-05-01
완료(예정)
2027-06-01

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.